Skip to main content
SpringerLink
Log in

Tarenflurbil in Patients with Mild Alzheimer’s Disease

  • Clinical Trial Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Neugroschl J, Sano M: An update on treatment and prevention strategies for Alzheimer’s disease. Curr Neurol Neurosci Rep 2009, 9(5):368–376.

    Article  PubMed  Google Scholar 

  2. Wilcock GK, Black SE, Hendrix SB, et al.: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol 2008, 7(6):483–493.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Sally Kerlin Professor of Neurology, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY, 10032, USA

    Karen Marder

Authors
  1. Karen Marder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen Marder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marder, K. Tarenflurbil in Patients with Mild Alzheimer’s Disease. Curr Neurol Neurosci Rep 10, 336–337 (2010). https://doi.org/10.1007/s11910-010-0130-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-010-0130-6

Keywords

Search

Navigation